Cargando…

The iterative lipid impact on inflammation in atherosclerosis

PURPOSE OF REVIEW: Lipid-mediated atherogenesis is hallmarked by a chronic inflammatory state. Low-density lipoprotein cholesterol (LDL-C), triglyceride rich lipoproteins (TRLs), and lipoprotein(a) [Lp(a)] are causally related to atherosclerosis. Within the paradigm of endothelial activation and sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraaijenhof, Jordan M., Hovingh, G. Kees, Stroes, Erik S.G., Kroon, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452331/
https://www.ncbi.nlm.nih.gov/pubmed/34392272
http://dx.doi.org/10.1097/MOL.0000000000000779
_version_ 1784570045065592832
author Kraaijenhof, Jordan M.
Hovingh, G. Kees
Stroes, Erik S.G.
Kroon, Jeffrey
author_facet Kraaijenhof, Jordan M.
Hovingh, G. Kees
Stroes, Erik S.G.
Kroon, Jeffrey
author_sort Kraaijenhof, Jordan M.
collection PubMed
description PURPOSE OF REVIEW: Lipid-mediated atherogenesis is hallmarked by a chronic inflammatory state. Low-density lipoprotein cholesterol (LDL-C), triglyceride rich lipoproteins (TRLs), and lipoprotein(a) [Lp(a)] are causally related to atherosclerosis. Within the paradigm of endothelial activation and subendothelial lipid deposition, these lipoproteins induce numerous pro-inflammatory pathways. In this review, we will outline the effects of lipoproteins on systemic inflammatory pathways in atherosclerosis. RECENT FINDINGS: Apolipoprotein B-containing lipoproteins exert a variety of pro-inflammatory effects, ranging from the local artery to systemic immune cell activation. LDL-C, TRLs, and Lp(a) induce endothelial dysfunction with concomitant activation of circulating monocytes through enhanced lipid accumulation. The process of trained immunity of the innate immune system, predominantly induced by LDL-C particles, hallmarks the propagation of the low-grade inflammatory response. In concert, bone marrow activation induces myeloid skewing, further contributing to immune cell mobilization and plaque progression. SUMMARY: Lipoproteins and inflammation are intertwined in atherogenesis. Elucidating the inflammatory pathways will provide new opportunities for therapeutic agents.
format Online
Article
Text
id pubmed-8452331
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-84523312021-09-28 The iterative lipid impact on inflammation in atherosclerosis Kraaijenhof, Jordan M. Hovingh, G. Kees Stroes, Erik S.G. Kroon, Jeffrey Curr Opin Lipidol ATHEROSCLEROSIS: CELL BIOLOGY AND LIPOPROTEINS: Edited by Mohamad Navab and Menno de Winther PURPOSE OF REVIEW: Lipid-mediated atherogenesis is hallmarked by a chronic inflammatory state. Low-density lipoprotein cholesterol (LDL-C), triglyceride rich lipoproteins (TRLs), and lipoprotein(a) [Lp(a)] are causally related to atherosclerosis. Within the paradigm of endothelial activation and subendothelial lipid deposition, these lipoproteins induce numerous pro-inflammatory pathways. In this review, we will outline the effects of lipoproteins on systemic inflammatory pathways in atherosclerosis. RECENT FINDINGS: Apolipoprotein B-containing lipoproteins exert a variety of pro-inflammatory effects, ranging from the local artery to systemic immune cell activation. LDL-C, TRLs, and Lp(a) induce endothelial dysfunction with concomitant activation of circulating monocytes through enhanced lipid accumulation. The process of trained immunity of the innate immune system, predominantly induced by LDL-C particles, hallmarks the propagation of the low-grade inflammatory response. In concert, bone marrow activation induces myeloid skewing, further contributing to immune cell mobilization and plaque progression. SUMMARY: Lipoproteins and inflammation are intertwined in atherogenesis. Elucidating the inflammatory pathways will provide new opportunities for therapeutic agents. Lippincott Williams & Wilkins 2021-10 2021-08-23 /pmc/articles/PMC8452331/ /pubmed/34392272 http://dx.doi.org/10.1097/MOL.0000000000000779 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle ATHEROSCLEROSIS: CELL BIOLOGY AND LIPOPROTEINS: Edited by Mohamad Navab and Menno de Winther
Kraaijenhof, Jordan M.
Hovingh, G. Kees
Stroes, Erik S.G.
Kroon, Jeffrey
The iterative lipid impact on inflammation in atherosclerosis
title The iterative lipid impact on inflammation in atherosclerosis
title_full The iterative lipid impact on inflammation in atherosclerosis
title_fullStr The iterative lipid impact on inflammation in atherosclerosis
title_full_unstemmed The iterative lipid impact on inflammation in atherosclerosis
title_short The iterative lipid impact on inflammation in atherosclerosis
title_sort iterative lipid impact on inflammation in atherosclerosis
topic ATHEROSCLEROSIS: CELL BIOLOGY AND LIPOPROTEINS: Edited by Mohamad Navab and Menno de Winther
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452331/
https://www.ncbi.nlm.nih.gov/pubmed/34392272
http://dx.doi.org/10.1097/MOL.0000000000000779
work_keys_str_mv AT kraaijenhofjordanm theiterativelipidimpactoninflammationinatherosclerosis
AT hovinghgkees theiterativelipidimpactoninflammationinatherosclerosis
AT stroeseriksg theiterativelipidimpactoninflammationinatherosclerosis
AT kroonjeffrey theiterativelipidimpactoninflammationinatherosclerosis
AT kraaijenhofjordanm iterativelipidimpactoninflammationinatherosclerosis
AT hovinghgkees iterativelipidimpactoninflammationinatherosclerosis
AT stroeseriksg iterativelipidimpactoninflammationinatherosclerosis
AT kroonjeffrey iterativelipidimpactoninflammationinatherosclerosis